DEA Proposes Placing Kratom Component in Schedule I Due to Public Safety Hazard

The Drug Enforcement Administration (DEA) has issued a notice of intent to temporarily place 7-hydroxymitragynine, a component of kratom, into Schedule I of the Controlled Substances Act. This temporary scheduling order is expected to take effect on August 5, 2026, and is being implemented to avoid an imminent hazard to public safety. The order will impose regulatory controls and administrative, civil, and criminal sanctions applicable to Schedule I substances on individuals handling 7-hydroxymitragynine above a specified threshold.

Context

Kratom, derived from the leaves of the Mitragyna speciosa tree, has been used for centuries in Southeast Asia for its stimulant and sedative properties. The active component, 7-hydroxymitragynine, has been associated with both therapeutic effects and potential risks, including addiction and adverse health effects. The DEA's action follows increasing reports of kratom-related health issues and fatalities, prompting regulatory scrutiny.

Why it matters

The DEA's proposal to classify 7-hydroxymitragynine as a Schedule I substance highlights growing concerns about public safety related to kratom use. This classification could significantly limit access to kratom for consumers and impact those who use it for pain relief or other purposes. The decision reflects ongoing debates about the safety and efficacy of kratom in the context of substance regulation.

Implications

If 7-hydroxymitragynine is officially classified as Schedule I, it may lead to increased penalties for possession and distribution, affecting users and businesses involved in the kratom market. This could also drive users to seek alternative substances, potentially leading to unregulated or unsafe options. The decision may also influence future research and discussions on the benefits and risks associated with kratom.

What to watch

As the temporary scheduling order is set to take effect in August 2026, stakeholders, including kratom users, vendors, and health professionals, will closely monitor developments. Public comments and potential legal challenges may arise as the DEA finalizes its decision. Additionally, state-level responses and legislative actions regarding kratom regulation could emerge in the lead-up to the effective date.